advertisement
Joshi et al. (352) compared the habit of members of the American Glaucoma Society in the use of antifibrotic agents in 1996 and in 2002. In 1996 a preference for mitomycin-C was reported. This had not changed significantly over six years. This seems to indicate that early or late bleb related complications do not seem to worry American glaucomatologists enough to reduce their use of mitomycine-C. That is: until a better option becomes available.